Table 1. In vitro and in vivo... | American Society of Hematology

Table 1.

In vitro and in vivo characteristics of monoclonal and polyclonal anti-D

Anti-D	IgG subclass	Agglutination titer^*	Epitope specificity	Dose tested in vivo, μg	Relative in vivo clearance potency, % (± SD)
Polyclonal	IgG1/IgG3	512	ND	5	100
13E10	IgG1	32	1^†	5	50 ± 23
25F5	IgG1	256	6/7	5	86 ± 8
21H9	IgG1	256	6/7^†	5	61 ± 15
46E7	IgG1	32	2	5	87 ± 9
19A5	IgG1	32	6/7^†	5	15 ± 19
				10	50 ± 28
				20	47 ± 8
13D2	IgG3	256	1^†	5	42 ± 16
24A5	IgG3	64	2^†	5	72 ± 20
26C1	IgG3	256	6/7	1	62 ± 21
				5	82 ± 11
				10	96 ± 14
Blend^‡				5	82 ± 4
				10	92 ± 3

Anti-D	IgG subclass	Agglutination titer^*	Epitope specificity	Dose tested in vivo, μg	Relative in vivo clearance potency, % (± SD)
Polyclonal	IgG1/IgG3	512	ND	5	100
13E10	IgG1	32	1^†	5	50 ± 23
25F5	IgG1	256	6/7	5	86 ± 8
21H9	IgG1	256	6/7^†	5	61 ± 15
46E7	IgG1	32	2	5	87 ± 9
19A5	IgG1	32	6/7^†	5	15 ± 19
				10	50 ± 28
				20	47 ± 8
13D2	IgG3	256	1^†	5	42 ± 16
24A5	IgG3	64	2^†	5	72 ± 20
26C1	IgG3	256	6/7	1	62 ± 21
				5	82 ± 11
				10	96 ± 14
Blend^‡				5	82 ± 4
				10	92 ± 3

IgG indicates immunoglobulin G; ND, not done.

Antibody concentration adjusted to 1 μg/mL.

Indicates probable epitope specificity.

Blend of 26C1, 46E7, and 25F5 (1:1:1).